Applied Therapeutics Inc (APLT) is looking forward to a strong quarter

With 0.77 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.4 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $2.9100 whereas the lowest price it dropped to was $2.6300. The 52-week range on APLT shows that it touched its highest point at $4.42 and its lowest point at $0.76 during that stretch. It currently has a 1-year price target of $9.50. Beta for the stock currently stands at 1.51.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of APLT was down-trending over the past week, with a drop of -13.14%, but this was up by 17.83% over a month. Three-month performance surged to 10.16% while six-month performance rose 73.72%. The stock gained 141.96% in the past year, while it has lost -19.10% so far this year. A look at the trailing 12-month EPS for APLT yields -1.32 with Next year EPS estimates of -0.87. For the next quarter, that number is -0.26. This implies an EPS growth rate of 28.98% for this year and 43.89% for next year.

Float and Shares Shorts:

At present, 77.23 million APLT shares are outstanding with a float of 54.45 million shares on hand for trading. On Jan 11, 2024, short shares totaled 3.63 million, which was 4.69% higher than short shares on Dec 14, 2023. In addition to ALT as the firm’s Altimmune, Inc., AULT serves as its Ault Alliance, Inc..

Institutional Ownership:

Through their ownership of 73.08% of APLT’s outstanding shares, institutional investors have majority control over the company.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for APLT since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With APLT analysts setting a high price target of $14.00 and a low target of $5.00, the average target price over the next 12 months is $9.50. Based on these targets, APLT could surge 416.61% to reach the target high and rise by 84.5% to reach the target low. Reaching the average price target will result in a growth of 250.55% from current levels.

Summary of Insider Activity:

Insiders traded APLT stock several times over the past three months with 1 Buys and 0 Sells. In these transactions, 300,000 shares were bought while 0 shares were sold. The number of buy transactions has increased to 8 while that of sell transactions has risen to 8 over the past year. The total number of shares bought during that period was 2,012,375 while 2,311,284 shares were sold.